Abstract
Acute rejection (AR) remains a common problem in lung transplantation (LTx) with AR rates generally being in the range of 40%. Induction therapy however is not uniformly applied due to lack of definitively proven efficacy and concern for infectious complications of over–immunosuppression in these patients. No fully reported trials have compared any form of induction therapy to placebo in a double-blind fashion in LTx. This study explored the tolerability and cumulative benefit of combining basiliximab with triple-drug therapy-cyclosporine (Neoral), azathioprine, and steroids.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
